CompletedPhase 1NCT00486382

Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India

Studying Leishmaniasis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Access to Advanced Health Institute (AAHI)
Principal Investigator
Shyam Sundar, MD
Banaras Hindu University
Intervention
Leish-111f + MPL-SE Adjuvant(biological)
Enrollment
36 target
Eligibility
18-54 years · All sexes
Timeline
2007 – 2008

Study locations (1)

Collaborators

Bill and Melinda Gates Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00486382 on ClinicalTrials.gov

Other trials for Leishmaniasis

Additional recruiting or active studies for the same condition.

See all trials for Leishmaniasis →

← Back to all trials